Results 231 to 240 of about 151,327 (305)

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids. [PDF]

J Neuroendocrinol
Baudin E, Durand A, Durand A, Buikhuisen W, Capdevila J, Caplin M, Deroose CM, Dromain C, Faggiano A, Filosso PL, Kaltsas G, Volante M, Walter T, Garcia-Carbonero R.   +13 more
europepmc   +1 more source

Neuroendocrine Tumors

Annals of Oncology, 2010
openaire   +2 more sources

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Editorial: Functional neuroendocrine tumors. [PDF]

Front Endocrinol (Lausanne)
Popovic B, Spada F, Singh A, Zibar Tomsic K.   +3 more
europepmc   +1 more source

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

Cancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Nobuyuki Katakami, Akira Kisohara, Masafumi Yamaguchi, Hirotaka Kuroki, Masamichi Sugimoto, Hisao Ashimura, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

Cancer Science, EarlyView.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota, Taku Naiki, Koji Hatano, Akira Yokomizo, Hiroaki Tsuchiya, Yoko Takahashi, Taku Nakayama, Masaki Yoshida, Hirotsugu Uemura   +8 more
wiley   +1 more source

Malnutrition and Sarcopenia in Patients with Neuroendocrine Tumors: A Comprehensive Review of Evidence. [PDF]

Biomolecules
Poulia KA, Spyroglou A, Violetis O, Mastorakos G, Alexandraki KI, Papavassiliou AG.   +5 more
europepmc   +1 more source

A Collateral Venous Pathway in Omental Arch of Barkow After Spleen Preserving Distal Pancreatectomy

ANZ Journal of Surgery, EarlyView.
Cartanese Carmine, Scaramuzzi Matteo, De Luca Raffaele, Mastrandrea Giovanni, Sollitto Mario   +4 more
wiley   +1 more source

Comparative Analysis of Incidental and Non‐Incidental Papillary Thyroid Microcarcinoma Outcomes: Implications on Management Recommendations

Clinical Endocrinology, EarlyView.
ABSTRACT Introduction Papillary thyroid microcarcinomas (PTMC) are defined by the World Health Organisation (WHO) as tumours measuring ≤ 10 mm. Incidental PTMCs, or lesions discovered postoperatively on histological examination, are less extensively studied compared with lesions diagnosed preoperatively through cytology, particularly in terms of ...
Emma A. Finnegan, Justin M. Hintze, Anne McGowan, James Gibney, Conall W. R. Fitzgerald, John Kinsella, Marie Louise Healy   +6 more
wiley   +1 more source